Life Sciences: Regulatory/Compliance
Global Guide 2024 : USA
Band 2
Email address
[email protected]Contact number
+1 617 951 7000About
Provided by Ropes & Gray LLP
Today’s life sciences industry faces myriad challenges, including complex regulation, steep competition and ever-changing technologies. Companies around the world turn to Ropes & Gray’s global life sciences group for internationally recognized counsel on virtually all matters impacting their businesses.
We work across practices and geographies to develop cutting-edge solutions that help our clients meet their business goals.
In addition to advising biotechnology, pharmaceutical and medical device companies, we also work with:
Investment banks, venture capital and private equity firms, royalty monetization firms, private investment and hedge funds, and individual investors focused on funding life sciences-related companies
Food, dietary supplement, cosmetics and consumer product companies
Academic medical centers and research institutions
Veterinary, agricultural and industrial applications
Drawing on resources in our offices around the globe, we focus on developing cutting-edge solutions to help clients meet their business goals. Our practice includes:
Mergers & acquisitions
Licensing, collaborations & joint ventures
Public and private financings and SEC compliance
FDA regulatory and health care compliance
China regulatory & compliance
Government enforcement / white collar crime
Intellectual property
Securities & futures enforcement
Antitrust
Tax
To learn more about our practice, please visit: https://www.ropesgray.com/practices/life-sciences.aspx
Chambers Review
Ropes & Gray provides an integrated international offering with a strong global focus on financial services, life sciences and pharmaceuticals. The firm's US offices act as its primary driving force for international work, with Boston and New York frequently leading cross-border work, typically coordinating global transactions for major private equity funds and corporations. Key areas of geographic strength include Asian markets, and Ropes & Gray is often considered a popular choice by US and Asian clients for investments from the USA into China and Japan, where the firm can also offer locally based US law-qualified experts. The US team also works in a seamless manner with the firm's London office, particularly for the funds and corporate side of the practice.
Included with the firm's strong global practice is a reputable healthcare and life sciences group. The firm is frequently engaged in transactional work involving those industries, acting for a mixture of company clients and investment funds. Recent work includes several complex cross-border matters, including acquisitions, joint ventures and investigation work for biotech and pharma companies which have involved the USA, the EU and Asian jurisdictions.
Strengths
Provided by Chambers
"Ropes & Gray understand the market better than most firms because of their various offices and wide client range."
"Ropes & Gray understand the laws in many countries, have offices and/or a network of lawyers in others, and can deliver advice in understandable and actionable language."
"The standard and quality of work is consistent across the entirety of the team."
"Ropes & Gray understand the market better than most firms because of their various offices and wide client range."
"Ropes & Gray understand the laws in many countries, have offices and/or a network of lawyers in others, and can deliver advice in understandable and actionable language."
"The standard and quality of work is consistent across the entirety of the team."
Notable Practitioners
Marc Rubenstein is considered one of the nation's leading experts on complex strategic licensing and collaborative research arrangements.
"Marc provides excellent service and is very knowledgeable in many matters."
Paul Kinsella has extensive experience representing life sciences companies in capital markets transactions and M&A.
"Paul is a phenomenal lawyer."
David McIntosh advises investors, businesses and research institutions on IP-driven transactions such as M&A, joint ventures, collaborations and licensing arrangements of all kinds.